Literature DB >> 3363466

Esophageal perforation due to pneumatic dilation for achalasia.

R E Miller1, H I Tiszenkel.   

Abstract

The initial treatment for achalasia in most centers is pneumatic dilation (PD). The most significant complication of PD is esophageal perforation (EP). During the past ten years, six patients were noted to have EP after PD at St. Luke's-Roosevelt Hospital Center. The cornerstone of treatment is early diagnosis. Operative repair, including suture of the perforation and modified Heller esophagomyotomy without anti-reflux procedure, is preferred. Details of this operation are presented. We have successfully managed five patients with EP after PD. A sixth patient died of unrecognized EP.

Entities:  

Mesh:

Year:  1988        PMID: 3363466

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  5 in total

1.  Management of esophageal perforation after pneumatic dilation for achalasia.

Authors:  D R Hunt; V L Wills; B Weis; J O Jorgensen; D J DeCarle; I J Coo
Journal:  J Gastrointest Surg       Date:  2000 Jul-Aug       Impact factor: 3.452

2.  Risk factors of oesophageal perforation during pneumatic dilatation for achalasia.

Authors:  E Borotto; M Gaudric; B Danel; J Samama; G Quartier; S Chaussade; D Couturier
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

3.  Outcome after perforation sustained during pneumatic dilatation for achalasia.

Authors:  H M Schwartz; C E Cahow; M Traube
Journal:  Dig Dis Sci       Date:  1993-08       Impact factor: 3.199

4.  Complications during pneumatic dilation for achalasia or diffuse esophageal spasm. Analysis of risk factors, early clinical characteristics, and outcome.

Authors:  L A Nair; J C Reynolds; H P Parkman; A Ouyang; B L Strom; E F Rosato; S Cohen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

5.  Perendoscopic pneumatic dilatation in achalasia: assessment of outcome using esophageal scintigraphy.

Authors:  B T Johnston; B J Collins; J S Collins; W R Ferguson
Journal:  Dysphagia       Date:  1992       Impact factor: 3.438

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.